Satellite Banner
Technology Networks Header
Monday, September 22, 2014
Technology Networks
 
Register | Sign in
Home Page > Videos > Results From Serum-Tumorautoantibody Profiling of Breast, Colon, Lung and Prostate Cancers Using a 16k Protein Array for Improving Minimal Invasive Diagnostics
  Videos

Return

Results From Serum-Tumorautoantibody Profiling of Breast, Colon, Lung and Prostate Cancers Using a 16k Protein Array for Improving Minimal Invasive Diagnostics
Austrian Institute of Technology GmbH

Andreas Weinhäusel, Senior Scientist, Austrian Institute of Technology GmbH

Abstract
In Europe there were an estimated 3.2 million new cases of cancer in 2008. The most commonly reported cases in Europe were colorectal cancers ( 13.6%), breast cancer (13.1%), lung cancer (12.2%) and prostate cancer (11.9%). These 4 big cancer entities make up more than 50% of all cancers. It is well accepted that early detection of cancer does improve patient survival, thus there is a pressing need to improve early cancer detection.  This can be best fulfilled by an easy and simple test suitable for minimal invasive testing. Tumour-associated antigens (TAA) can be detected prior to clinical diagnosis and thus would be ideal biomarkers for early detection of cancer using only a few microliters of a patient's serum.We have developed an 16k protein-microarray using the UNIPEX human cDNA expression library. During methods optimization we studies the influence of different serum and plasma sampling procedures and finally came up with an optimized protocol using purified IgG from samples for TAA profiling. This protocol enabled definition of TAA classifier panels with very promising classification success of patients versus controls for the big 4 cancer entities. Currently we set up targeted microarrays for validation of our screening results. In addition in silico design of antigenic peptides from sero-reactive clone-sequences has also been conducted and preliminary data enabled an improved classification compared to corresponding proteins. Thus multiplexed protein and peptide based serum-analyses could further improve cancer diagnostics

Request more information
Company product page



For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here

Scientific News
How Epigenetic Memory is Passed Across Generations
Researchers traced markers of gene repression through cell division and showed that both sperm and eggs transmit a memory of gene repression to embryos.
Spontaneous Mutations in Key Brain Gene are a Cause of Autism
In addition, there is a direct link between TBR1 and FOXP2, a well-known language-related protein, researchers report.
Asuragen’s Xpansion Interpreter® Test Study of 1,040 Transmissions of Fragile X Alleles
Study reveals personalized risks for expansion from parent to child.
Genetics Reveals Patients Susceptible to Drug-induced Pancreatitis
Doctors have discovered that patients with a particular genetic variation are four times more likely to develop pancreatitis if they are prescribed a widely used group of drugs.
Blood Test To Diagnose Depression
Test identifies nine blood markers tied to depression; predicts who will benefit from therapy.
Genetic Testing for Prostate Cancer
Genetic testing can identify men at six-fold increased risk of prostate cancer.
Zebrafish Genes Linked To Human Respiratory Diseases
Genes have been discovered which may be synonymous with the genes for developing hair-like structures in the human airway.
Ancient Vertebrate Uses Familiar Tools
Sea lamprey studies show remarkably conserved gene expression patterns in jawless versus jawed vertebrates.
Study Aims to Develop Breath Test for COPD
A new clinical iniative, lead by NYU Langone Medical Center, aims to determine a breath test’s effectiveness to identify volatile organic compounds (VOCs) in human breath that are biomarkers of chronic obstructive pulmonary disease (COPD).
Clinical Utility of Myriad myPath(TM) Melanoma Test Demonstrated
Test reduced indeterminate cases by 76 percent and changed treatment in 35 percent of cases.
Scroll Up
Scroll Down
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv